drugset / Trial / NCT00494897

PETHEMA LAL-RI/96: Treatment for Patients With Standard Risk Acute Lymphoblastic Leukemia

NCT00494897

Phase 4 Completed 374 enrolled PETHEMA Foundation
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The objective of current protocol is try improve the results of chemotherapy treatment in patients with ALL wich is not indicated the peripheral stem cell transplant in first remission, with an intensive consolidation follow by re-inductions.

Timeline

Start
1996-06
Primary completion
2007-05
Completion
2007-12

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Cyclophosphamide Other / unclassified 500 mg/m2 Intravenous
Subject Cyclophosphamide Other / unclassified 600 mg/m2 Intravenous
Subject Cytarabine Small molecule 500 mg/m2 Intravenous
Subject Daunorubicin Small molecule 30 mg/m2 Intravenous
Subject MERCAPTOPURINE ANHYDROUS Small molecule 50 mg/m2 Oral
Subject Methotrexate Small molecule 20 mg Intravenous
Subject Methotrexate Small molecule 1.5 g Intravenous
Subject Methotrexate Small molecule 3 g Intravenous
Subject Prednisone Other / unclassified 60 mg/m2 Oral
Subject Vincristine Small molecule 1.5 mg/m2 Intravenous
Subject asparaginase Protein / enzyme biologic 10000 unknown Intramuscular
Subject asparaginase Protein / enzyme biologic 20000 unknown Intramuscular